On December 4, 2023, Nanobiotix S.A. closed the transaction. The company issued 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares at a price $5.36 for a gross proceeds $4,830,732.16 in its second and final tranche, the company has issued total 4,664,179 shares for total gross proceeds of $24,999,999.44 in the transaction.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.42 EUR | -1.28% | -5.74% | -18.37% |
Apr. 25 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 | |
Apr. 24 | Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.37% | 277M | |
+1.34% | 42.86B | |
+11.93% | 42.74B | |
+45.15% | 41.36B | |
-8.83% | 27.68B | |
+7.28% | 25.15B | |
-23.61% | 18.63B | |
+29.52% | 12.37B | |
-2.21% | 11.92B | |
+7.34% | 11.21B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.